Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) earlier this week announced significant progress in their collaboration with Rain Cage. The company disclosed that Rain Cage has successfully created vanadium metal fullerenes at scale, a world-first achievement. This breakthrough is expected to revolutionize the development of MRI and CT scan drugs by making them more effective and safer.
The company's CEO, Brent Willis, highlighted that fullerenes can be made water and lipid-soluble, allowing for new injectable drug formulations. Studies have shown that gadolinium fullerenes can increase sensitivity by 500 times, enabling lower doses and reducing side effects. This innovation addresses current gadolinium drugs' safety issues, which can cause brain complications.
Willis called it a “scientific breakthrough” in a recent interview with Proactive.
“It's going to have major impact on nanoscience in many industries,” Willis said.
Voyageur Pharmaceuticals is planning to develop gadolinium, bismuth, and iodine molecules using this technology, with experimental work set to begin in 2024. The company emphasized that while the work is experimental, successful replication of vanadium's achievements could lead to significant advancements in radiological scans' precision and clarity.
The potential to replace current iodine-based drugs with these new formulations represents a significant opportunity for the company. Enhanced radiological scan clarity could lead to earlier disease detection and improved patient outcomes.
“We'll just keep moving down the path and try to repeat what they did with vanadium and see what we can do with gadolinium and bismuth,” Willis said.
“That's very impactful as it could replace the iodine drugs that are currently being used today.”
